Recently, a novel coronavirus (2019-nCoV), officially known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China. Despite drastic containment measures, the spread of this virus is ongoing. SARS-CoV-2 is the aetiological agent of coronavirus disease 2019 (COVID-19) characterised by pulmonary infection in humans. The efforts of international health authorities have since focused on rapid diagnosis and isolation of patients as well as the search for therapies able to counter the most severe effects of the disease. In the absence of a known efficient therapy and because of the situation of a public-health emergency, it made sense to investigate the possible effect of chloroquine/hydroxychloroquine against SARS-CoV-2 since this molecule was previously described as a potent inhibitor of most coronaviruses, including SARS-CoV-1. Preliminary trials of chloroquine repurposing in the treatment of COVID-19 in China have been encouraging, leading to several new trials. Here we discuss the possible mechanisms of chloroquine interference with the SARS-CoV-2 replication cycle.
Keywords: COVID-19; Chloroquine; Coronavirus; SARS-CoV-2.
Copyright © 2020. Published by Elsevier B.V.
Conflict of interest statement
Declaration of Competing Interest None declared.
Features, Evaluation and Treatment Coronavirus (COVID-19).2020 Mar 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. StatPearls. 2020 Jan–. PMID: 32150360 Free Books & Documents. Review.
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.Mil Med Res. 2020 Mar 13;7(1):11. doi: 10.1186/s40779-020-00240-0. Mil Med Res. 2020. PMID: 32169119 Free PMC article. Review.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges.Int J Antimicrob Agents. 2020 Mar;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924. Epub 2020 Feb 17. Int J Antimicrob Agents. 2020. PMID: 32081636
Coronavirus Disease 2019: Coronaviruses and Blood Safety.Transfus Med Rev. 2020 Feb 21:S0887-7963(20)30014-6. doi: 10.1016/j.tmrv.2020.02.003. Online ahead of print. Transfus Med Rev. 2020. PMID: 32107119 Review.
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.J Microbiol Immunol Infect. 2020 Mar 4:S1684-1182(20)30040-2. doi: 10.1016/j.jmii.2020.02.012. Online ahead of print. J Microbiol Immunol Infect. 2020. PMID: 32173241 Review.